Medication Guide App

Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr. Lauren Krupp, Professor of Neurology at Stony Brook University, will present data from Acorda's Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at their analyst and investor reception on May 2, 2007. This reception will follow a presentation of this data at the American Academy of Neurology (AAN) annual meeting.

Dr. Krupp's presentation will begin at 7:00 pm Eastern Time (ET) and will be able via a live webcast at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c= 194451&eventID=1529938

Archived versions of the webcast will be available for 90 days on our website at http://phx.corporate-ir.net/phoenix.zhtml?c= 194451&p=irol-irhome. (Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove extra spaces if they exist.)

The platform presentation of the Phase 3 clinical trial of Fampridine-SR data at the AAN meeting will take place on May 2, 2007 at 4:15 pm ET. This abstract was selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. This presentation was also selected for a second highlights session, Multiple Sclerosis Scientific Topic Highlights, to be presented on May 3, 2007 at 7:00 pm ET. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Contact

Acorda Therapeutics
Erica Wishner, 914-347-4300 ext. 162
ewishner@acorda.com

Posted: April 2007

View comments

Hide
(web3)